Login to Your Account



Biotechs Urged to Weigh in as Supreme Court Considers Myriad

By Marie Powers
Staff Writer

Tuesday, December 4, 2012

"Hoping against hope" the Supreme Court is simply signaling a need to provide greater guidance to the Federal Circuit is one way to view the high court's decision to grant cert in Association for Molecular Pathology v. Myriad Genetics Inc., according to Kevin E. Noonan, a partner in the Chicago office of McDonnell Boehnen Hulbert & Berghoff LLP.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription